Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on commercializing value-added products in specialty therapeutic areas in Canada. The company markets and distributes ZIMED PF, a preservative-free bimatoprost prescription drug for the treatment of glaucoma. It also develops REV-0100 for the treatment of stargardt disease that is in pre-clinical trial. The company has a strategic collaboration with reVision for the development of a therapy for stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Metrics to compare | AQS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAQSPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.2x | −2.6x | −0.6x | |
PEG Ratio | −0.01 | 0.00 | 0.00 | |
Price/Book | −0.1x | 0.7x | 2.6x | |
Price / LTM Sales | 1.6x | 1.1x | 3.2x | |
Upside (Analyst Target) | - | 42.9% | 46.2% | |
Fair Value Upside | Unlock | 23.6% | 7.0% | Unlock |